Loading…

Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group

Saved in:

Bibliographic Details
Published in:	Leukemia 2020-03, Vol.34 (3), p.953-956
Main Authors:	Eichenauer, Dennis A., Plütschow, Annette, Fuchs, Michael, Hartmann, Sylvia, Hansmann, Martin-Leo, Böll, Boris, von Tresckow, Bastian, Borchmann, Peter, Engert, Andreas
Format:	Article
Language:	English
Subjects:	631/67/1990/291/1556 692/308/2779/109/1941 692/699/1541/1990/291/1556 Adult Aged Antigens, CD20 - metabolism Cancer Cancer Research Critical Care Medicine Development and progression Disease Progression Drug therapy Female Follow-Up Studies Germany Hematology Hodgkin Disease - therapy Hodgkin's disease Hodgkin's lymphoma Humans Intensive Internal Medicine Letter Lymphocytes Lymphocytes - cytology Lymphoma Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Neoplasm Recurrence, Local Oncology Oncology, Experimental Progression-Free Survival Prospective Studies Retrospective Studies Rituximab Rituximab - therapeutic use Salvage Therapy Targeted cancer therapy Treatment Outcome Young Adult
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!